This week, 8 Health Care Equipment & Supplies stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Varian Medical Systems, Inc.’s (VAR) rating worsens to a D from the company’s C rating a week ago. Varian Medical Systems, Inc. manufactures and sells equipment and software products for treating cancer with radiotherapy and radiosurgery. For more information, get Portfolio Grader’s complete analysis of VAR stock.
This is a rough week for Haemonetics Corporation (HAE). The company’s rating falls to D from the previous week’s C. Haemonetics Corporation designs, manufactures, and markets automated blood processing systems. For more information, get Portfolio Grader’s complete analysis of HAE stock.
Oxford Immunotec Global PLC (OXFD) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of OXFD stock.
This week, Derma Sciences, Inc. (DSCI) drops from a D to a F rating. Derma Sciences, Inc. markets and sells a range of skin care, wound management, and specialty securement devices. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DSCI stock.
RTI Surgical, Inc. (RTIX) declines this week from a C to a D. RTI Surgical, Inc. produces orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. For more information, get Portfolio Grader’s complete analysis of RTIX stock.
Slipping from a C to a D rating, TransEnterix, Inc. (TRXC) takes a hit this week. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRXC stock.
Dehaier Medical Systems Ltd. (DHRM) experiences a ratings drop this week, going from last week’s C to a D. Dehaier Medical Systems Ltd. engages in the development and distribution of medical devices and related products in the People’’s Republic of China. The company also gets F’s in sales growth, operating margin growth, earnings growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DHRM stock.
ERBA Diagnostics, Inc. (ERB) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in sales growth, operating margin growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of ERB stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
